← Eichor
Condition: Myasthenia Gravis Synced from ClinicalTrials.gov · July 27, 2026

Recruiting studies: Myasthenia Gravis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Markers of Favorable Response to FcRn Inhibitors(INFORM)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06685055A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod Dur
Phase N/A · 4 location(s) · argenx · NCT06299748Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"
Phase N/A · 1 location(s) · Institut de Myologie, France · NCT06866652Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myastheni
Phase 4 · 12 location(s) · UCB Biopharma SRL · NCT07246564Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children Wit
Phase 2/Phase 3 · 25 location(s) · argenx · NCT04833894Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT07411963A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Phase 1/Phase 2 · 25 location(s) · ImmunAbs Inc. · NCT07250750Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
Phase N/A · 7 location(s) · AstraZeneca · NCT07247279Study of Myasthenic Crisis in China
Phase N/A · 1 location(s) · Huashan Hospital · NCT04837625A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Phase 2/Phase 3 · 20 location(s) · argenx · NCT06392386A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Phase 3 · 112 location(s) · Janssen Research & Development, LLC · NCT04951622The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia Gravis
NA · 1 location(s) · Cheng, yu-ting · NCT06881173ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip
Phase N/A · 18 location(s) · argenx · NCT07294170Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Phase N/A · 1 location(s) · Assiut University · NCT05214612A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Phase 1 · 6 location(s) · Kite, A Gilead Company · NCT07304154Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT06815133Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Phase 3 · 1 location(s) · Clinique Neuro-Outaouais · NCT06765161Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
Phase 4 · 1 location(s) · University of Colorado, Denver · NCT06860633ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With
Phase 2 · 15 location(s) · argenx · NCT07284420Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Phase 3 · 15 location(s) · Janssen Research & Development, LLC · NCT07217587A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Gener
Phase 3 · 129 location(s) · Novartis Pharmaceuticals · NCT06744920Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
NA · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07470151Myasthenia Gravis Foundation of America Global MG Patient Registry
Phase N/A · 1 location(s) · Myasthenia Gravis Foundation of America · NCT06617741Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Phase 1 · 1 location(s) · Ting Chang, MD · NCT06371040A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Phase 3 · 1 location(s) · Dianthus Therapeutics · NCT07647510Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Phase 1 · 1 location(s) · Polina Stepensky · NCT07085676A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Phase 2/Phase 3 · 19 location(s) · Janssen Research & Development, LLC · NCT05265273A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Phase 3 · 1 location(s) · RemeGen Co., Ltd. · NCT07249632Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06941584
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.